H3C2
H3C2 (Histone H3.1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Bladder & urothelial cancer, Oesophageal cancer and 5 more.
Overview
Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability.
CIViC holds 7 clinical evidence items and 1 assertion across 1 variant. Open Targets scores its association with cancer at 0.73 (direct and indirect evidence; datatypes literature 0.04, affected pathway 0.76, somatic mutation 0.78). IntOGen calls it a driver in 5 cohorts (4 activating, 1 loss-of-function), covering Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Oesophageal Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · H3C2 (Histone H3.1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Bladder & urothelial cancer, Oesophageal cancer and 5 more.
- 1 · What it is
H3C2 (Histone H3.1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Bladder & urothelial cancer, Oesophageal cancer and 5 more.
- 2 · What goes wrong in cancer
Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template.
- 3 · How drugs use it
No product in this corpus aims at H3C2 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:4776 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P68431 (protein name, function text, keywords and locations (REST API)); CIViC gene H3C2 (7 evidence items, 1 assertions, 1 variants; diseases: Diffuse Midline Glioma, H3 K27-altered, Glioblastoma, Anaplastic Astrocytoma, Brain Glioblastoma Multiforme, Diffuse Astrocytoma (GraphQL API, CC0)); Open Targets ENSG00000286522 (association with cancer (MONDO_0004992) 0.73; per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.51, breast cancer 0.64 (GraphQL API, CC0)); IntOGen H3C2 (driver in 5 cohorts (Act 4, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. Location: Nucleus; Chromosome (UniProt). Locus 6p22.2 (HGNC).
- Breast cancer: Open Targets association 0.64 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA)
- Bladder & urothelial cancer: IntOGen driver in 2 cohorts (BLCA)
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Non-Hodgkin lymphoma: Open Targets association 0.51 with non-Hodgkin lymphoma (MONDO_0018908)
- Diffuse midline glioma, H3 K27-altered: CIViC evidence names this disease
- Glioma & glioblastoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 4 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 7 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Anaplastic Astrocytoma; Brain Glioblastoma Multiforme; Diffuse Astrocytoma.
Latest papers
topQuery for this target: (TITLE:"H3C2" OR ABSTRACT:"H3C2" OR TITLE:"H3 clustered histone 2" OR ABSTRACT:"H3 clustered histone 2" OR TITLE:"Histone H3.1" OR ABSTRACT:"Histone H3.1" OR TITLE:"H3/l" OR ABSTRACT:"H3/l" OR TITLE:"H3FL" OR ABSTRACT:"H3FL" OR TITLE:"HIST1H3B" OR ABSTRACT:"HIST1H3B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about H3C2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetHLA-B
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Non-Hodgkin lymphoma (all types), CIViC.
- TargetNUMA1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Breast cancer (all types), IntOGen.
- TargetZNF750
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
- TargetCDX2
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, CIViC, IntOGen.
- TargetNBEA
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Breast cancer (all types), IntOGen.
- TargetTGFBR1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
- TargetNCOA2
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Breast cancer (all types), IntOGen.
- TargetKAT6A
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Breast cancer (all types), IntOGen.